|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM163721084 |
| 003 |
DE-627 |
| 005 |
20231223100948.0 |
| 007 |
tu |
| 008 |
231223s2006 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed24n0546.xml
|
| 035 |
|
|
|a (DE-627)NLM163721084
|
| 035 |
|
|
|a (NLM)16797237
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Watanabe, Tomoko
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a CD52 is a novel costimulatory molecule for induction of CD4+ regulatory T cells
|
| 264 |
|
1 |
|c 2006
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 26.09.2006
|
| 500 |
|
|
|a Date Revised 03.01.2021
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a We previously reported that 4C8 monoclonal antibody (mAb) provides a costimulatory signal to human CD4+ T cells and consequently induces regulatory T (Treg) cells, which are hypo-responsive and suppress the polyclonal response of bystander CD4+ cells in a contact-dependent manner. In this study, we identified the antigen of 4C8 mAb as CD52. Costimulation with Campath-1H, a humanized anti-CD52 mAb, also induced Treg cells. Anti-CD52-induced Treg cells suppressed the proliferation of both CD4+ and CD8+ T cells provided with polyclonal or allogeneic stimulation. When Treg cells were induced from Staphylococcal enterotoxin B (SEB) treated cells, they suppressed the response to SEB more efficiently than that to another superantigen, SEA. Furthermore, anti-CD52-induced Treg cells could be expanded by culture with IL-2 followed by CD52-costimulation, and co-injection of expanded Treg cells suppressed lethal xenogeneic graft versus host disease (GvHD) reactions in SCID mice caused by human peripheral blood mononuclear cells (PBMCs)
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
7 |
|a 4C8 antigen, human
|2 NLM
|
| 650 |
|
7 |
|a Antibodies, Monoclonal
|2 NLM
|
| 650 |
|
7 |
|a Antibodies, Monoclonal, Humanized
|2 NLM
|
| 650 |
|
7 |
|a Antibodies, Neoplasm
|2 NLM
|
| 650 |
|
7 |
|a Antigens, CD
|2 NLM
|
| 650 |
|
7 |
|a Antigens, Neoplasm
|2 NLM
|
| 650 |
|
7 |
|a CD52 Antigen
|2 NLM
|
| 650 |
|
7 |
|a CD52 protein, human
|2 NLM
|
| 650 |
|
7 |
|a Enterotoxins
|2 NLM
|
| 650 |
|
7 |
|a Epitopes, T-Lymphocyte
|2 NLM
|
| 650 |
|
7 |
|a FOXP3 protein, human
|2 NLM
|
| 650 |
|
7 |
|a Forkhead Transcription Factors
|2 NLM
|
| 650 |
|
7 |
|a Glycoproteins
|2 NLM
|
| 650 |
|
7 |
|a Interleukin-2
|2 NLM
|
| 650 |
|
7 |
|a enterotoxin B, staphylococcal
|2 NLM
|
| 650 |
|
7 |
|a 39424-53-8
|2 NLM
|
| 650 |
|
7 |
|a Alemtuzumab
|2 NLM
|
| 650 |
|
7 |
|a 3A189DH42V
|2 NLM
|
| 700 |
1 |
|
|a Masuyama, Jun-ichi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Sohma, Yoshiaki
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Inazawa, Hiroko
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Horie, Kaori
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kojima, Kumiko
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Uemura, Yasunori
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Aoki, Yumi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kaga, Shuji
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Minota, Seiji
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Tanaka, Toshiyuki
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yamaguchi, Yasunori
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kobayashi, Tetsuto
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Serizawa, Isao
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 120(2006), 3 vom: 04. Sept., Seite 247-59
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:120
|g year:2006
|g number:3
|g day:04
|g month:09
|g pages:247-59
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 120
|j 2006
|e 3
|b 04
|c 09
|h 247-59
|